Literature DB >> 10195374

Tyr-Ala-Hexarelin, a synthetic octapeptide, possesses the same endocrine activities of Hexarelin and GHRP-2 in humans.

E Arvat1, L Di Vito, F Lanfranco, F Broglio, R Giordano, A Benso, G P Muccioli, R Deghenghi, E Ghigo.   

Abstract

Hexarelin (HEX) and GHRP-2 are two synthetic hexapeptides, superanalogs of GHRP-6, belonging to GH secretagogue (GHS) family. GHS act via specific receptors at both the pituitary and the hypothalamic level to stimulate GH release both in animals and in humans. However, GHS also possess significant PRL- and ACTH/cortisol-releasing activity. Tyr-Ala-HEX as well as Tyr-Ala-GHRP-6 are, in turn, synthetic octapeptides generally used to perform binding studies because of their easy iodination. However, their endocrine activities have never been studied in humans. To clarify the endocrine activities of Tyr-Ala-HEX, in 7 young adult volunteers we compared the effects of the maximal effective dose of HEX (2.0 microg/kg i.v.) or GHRP-2 (2.0 microg/kg i.v.) with the same one of Tyr-Ala-HEX on GH, PRL, ACTH and cortisol levels. Basal GH, PRL, ACTH and cortisol levels in all testing sessions were similar. The administration of placebo did not modify hormonal levels. HEX and GHRP-2 administration induced the well known strong GH response (Cmax, mean+/-SE: 77.3+/-6.0 and 74.1+/-12.1 microg/l; AUC, mean+/-SE: 2596.7+/-251.1 and 2480.0+/-343.6 microg*min/l). These responses were similar to that induced by Tyr-Ala-HEX (63.7+/-18.5 microg/l; 1986.6+/-622.4 microg*min/l). Moreover, HEX, GHRP-2 and Tyr-Ala-HEX had the same significant stimulatory effect on PRL (14.9+/-2.5, 12.3+/-2.0 and 10.0+/-1.5 microg/l; 497.8+/-61.8, 480.4+/-66.9 and 415.8+/-58.5 microg*min/l), ACTH (48.0+/-10.1, 51.4+/-10.6 and 44.9+/-12.2 pg/ml; 1531.6+/-235.7, 1586.7+/-277.0 and 1338.1+/-164.5 pg*min/ml) and cortisol (179.9+/-10.0, 181.2+/-14.1 and 149.7+/-20.1 microg/l; 8465.0+/-406.6, 8689.2+/-788.1 and 6295.2+/-797.0 microg*min/l). Also the mean Tmax of the endocrine responses to HEX, GHRP-2 and Tyr-Ala-HEX were similar. In conclusion, the present results demonstrate that in humans Tyr-Ala-HEX is a GH secretagogue as potent as HEX and GHRP-2, two GHRP-6 superanalogs. Tyr-Ala-HEX also shares with HEX and GHRP-2 the same PRL- ACTH- and cortisol-releasing activity.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10195374     DOI: 10.1007/BF03350886

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  42 in total

1.  Adrenocorticotropin- and cortisol-releasing effect of hexarelin, a synthetic growth hormone-releasing peptide, in normal subjects and patients with Cushing's syndrome.

Authors:  E Ghigo; E Arvat; J Ramunni; A Colao; L Gianotti; R Deghenghi; G Lombardi; F Camanni
Journal:  J Clin Endocrinol Metab       Date:  1997-08       Impact factor: 5.958

Review 2.  Growth hormone-releasing peptides.

Authors:  E Ghigo; E Arvat; G Muccioli; F Camanni
Journal:  Eur J Endocrinol       Date:  1997-05       Impact factor: 6.664

3.  On the actions of the growth hormone-releasing hexapeptide, GHRP.

Authors:  C Y Bowers; A O Sartor; G A Reynolds; T M Badger
Journal:  Endocrinology       Date:  1991-04       Impact factor: 4.736

4.  Reduction of the somatotrope responsiveness to GHRH and Hexarelin but not to arginine plus GHRH in hyperprolactinemic patients.

Authors:  S Grottoli; P Razzore; E Arvat; S E Oleandri; R Rossetto; E Ciccarelli; F Camanni; E Ghigo
Journal:  J Endocrinol Invest       Date:  1997-11       Impact factor: 4.256

5.  Widespread transcription of the growth hormone-releasing peptide receptor gene in neuroendocrine human tumors.

Authors:  Y de Keyzer; F Lenne; X Bertagna
Journal:  Eur J Endocrinol       Date:  1997-12       Impact factor: 6.664

6.  Influence of beta-adrenergic agonists and antagonists on the GH-releasing effect of Hexarelin in man.

Authors:  E Arvat; L Gianotti; J Ramunni; L DiVito; R Deghenghi; F Camanni; E Ghigo
Journal:  J Endocrinol Invest       Date:  1996-01       Impact factor: 4.256

7.  The growth hormone secretagogue, L-692,429, induces phosphatidylinositol hydrolysis and hormone secretion by human pituitary tumors.

Authors:  E F Adams; B Petersen; T Lei; M Buchfelder; R Fahlbusch
Journal:  Biochem Biophys Res Commun       Date:  1995-03-17       Impact factor: 3.575

8.  Influence of galanin and serotonin on the endocrine response to Hexarelin, a synthetic peptidyl GH-secretagogue, in normal women.

Authors:  E Arvat; B Maccagno; J Ramunni; F Broglio; F Lanfranco; R Giordano; A Benso; R Deghenghi; E Ghigo
Journal:  J Endocrinol Invest       Date:  1998-11       Impact factor: 4.256

9.  Growth hormone (GH)-releasing hormone secretion is stimulated by a new GH-releasing hexapeptide in sheep.

Authors:  V Guillaume; E Magnan; M Cataldi; A Dutour; N Sauze; M Renard; H Razafindraibe; B Conte-Devolx; R Deghenghi; V Lenaerts
Journal:  Endocrinology       Date:  1994-09       Impact factor: 4.736

10.  Regulation of His-dTrp-Ala-Trp-dPhe-Lys-NH2 (GHRP-6)-induced GH secretion in the rat.

Authors:  F Mallo; C V Alvarez; L Benitez; B Burguera; R Coya; F F Casanueva; C Dieguez
Journal:  Neuroendocrinology       Date:  1993       Impact factor: 4.914

View more
  6 in total

1.  Somatostatin octapeptides (lanreotide, octreotide, vapreotide, and their analogs) share the growth hormone-releasing peptide receptor in the human pituitary gland.

Authors:  R Deghenghi; M Papotti; E Ghigo; G Muccioli; V Locatelli
Journal:  Endocrine       Date:  2001-02       Impact factor: 3.633

Review 2.  Growth hormone-releasing hormone and growth hormone secretagogue-receptor ligands: focus on reproductive system.

Authors:  E Arvat; L Gianotti; R Giordano; F Broglio; M Maccario; F Lanfranco; G Muccioli; M Papotti; A Graziani; E Ghigo; R Deghenghi
Journal:  Endocrine       Date:  2001-02       Impact factor: 3.633

3.  Hexarelin protects H9c2 cardiomyocytes from doxorubicin-induced cell death.

Authors:  N Filigheddu; A Fubini; G Baldanzi; S Cutrupi; C Ghè; F Catapano; F Broglio; A Bosia; M Papotti; G Muccioli; E Ghigo; R Deghenghi; A Graziani
Journal:  Endocrine       Date:  2001-02       Impact factor: 3.633

4.  Cortistatin, but not somatostatin, binds to growth hormone secretagogue (GHS) receptors of human pituitary gland.

Authors:  R Deghenghi; M Papotti; E Ghigo; G Muccioli
Journal:  J Endocrinol Invest       Date:  2001-01       Impact factor: 4.256

5.  Acute cardiovascular and hormonal effects of GH and hexarelin, a synthetic GH-releasing peptide, in humans.

Authors:  G Bisi; V Podio; M R Valetto; F Broglio; G Bertuccio; G Del Rio; E Arvat; M F Boghen; R Deghenghi; G Muccioli; H Ong; E Ghigo
Journal:  J Endocrinol Invest       Date:  1999-04       Impact factor: 4.256

Review 6.  Biologic activities of growth hormone secretagogues in humans.

Authors:  E Ghigo; E Arvat; R Giordano; F Broglio; L Gianotti; M Maccario; G Bisi; A Graziani; M Papotti; G Muccioli; R Deghenghi; F Camanni
Journal:  Endocrine       Date:  2001-02       Impact factor: 3.925

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.